BODi's Nutrition Pivot: Fishing the Ocean While the Stock Sinks
The Beachbody Company posts a fourth straight profitable quarter on a nutrition-led, GLP-1-tilted turnaround — but the tape is still voting against it.
BODI · Earnings Call · 2026-08-10
BODi's Nutrition Pivot: Fishing the Ocean While the Stock Sinks
The Beachbody Company reported a fourth consecutive profitable quarter, but the tape keeps voting the other way. Q2 2026 revenue of $49.6M, adjusted EBITDA of $6.7M (a 13.4% margin — the fourth straight double-digit quarter), and net income of $1.4M all landed at or above the high end of guidance. Yet the stock sits roughly 99% below its February 2021 peak of $777 and has lost 37.9% over the last 90 days. The market is not yet buying the turnaround even as the P&L says it is real.
From lake to ocean
The story this quarter is a genuine strategic re-architecture: BODi is repositioning from a digital-fitness-subscription company into a retail rollout-driven, nutrition-first multichannel brand. Executive Chairman Mark Goldston framed it simply:
The digital fitness category is a $13 billion market, and the nutritional supplement category is a $164 billion market. That's like a lake versus an ocean.
That pivot has been telegraphed over the past year — in August 2025 Goldston noted “Shakeology is a brand that has cumulatively done... $4 billion in sales... and it has never been sold in the retail marketplace in brick-and-mortar” — Mark R. Goldston, Executive Chairman · 2025-08-06 — but this quarter it hit critical mass with actual store doors: Sprouts expanded to 131 locations with reorders, Vitamin Shoppe came in across 481 stores weeks ahead of plan, and distribution partnerships with KeHE and UNFI open the grocery channel. The P90X supplement line hit Amazon at sub-$40 price points, and the Insanity Liquid Shock / P90X energy drink Southern California test begins late Q3/Q4.
The GLP-1 wedge
The newest and most differentiated piece is the GLP 1 angle. BODi is deliberately courting the GLP-1 weight-loss population — among the hottest themes in the market right now, with obesity-complex names including patients with obesity appearing among 30-day advancers in the global tape. Carl Daikeler explained: “That very much includes GLP-1 users who the data shows are statistically undexercising... our super food protein shake, Shakeology, is seeing real demand from that same GLP-1 audience.” — Carl Daikeler, Co-Founder and Chief Executive Officer · 2026-08-10
This is BODi's clever wedge: most GLP-1 plays are pharma, but BODi offers the complementary fitness-content-and-nutrition stack — the Minute BODi microdose catalog of 5-to-10-minute home workouts, plus a protein shake that helps preserve muscle on a calorie deficit. It is a tailor-made pitch for a population that needs short, home-based resistance training.
Underneath the growth narrative, operations are running leaner. The Shopify migration, completed at the end of Q1, is now the conversion engine — Carl: “We are rapidly iterating... have one of the best companies that works with Shopify clients to make improvements to our landing pages so that we can increase our conversion.” — Carl Daikeler, Co-Founder and Chief Executive Officer · 2026-08-10 The legacy MLM seller-compensation burden has burned off, and media spend is being reallocated toward nutrition, where customer acquisition costs are structurally lower.
A balance sheet in its best shape in years
Cash of $32.4M against total debt of roughly $23.6M puts BODi in a net cash position of $8.8M, and the August 3 amendment to the Tiger Finance credit agreement lowered the covenant hurdle by about $7M. Goldston: “we renegotiated the covenant package so that the thresholds are even lower... It buys us $7-plus million of additional cushion.” — Mark Goldston, Executive Chairman · 2026-08-10 Meanwhile, the cost base has been reset: operating margin reached 5.7%, gross margin held at 71.8% 71.8%, and effective SG&A ran at roughly 15% of revenue this quarter — a fraction of the 40%-plus selling-and-marketing load of the MLM era.
The tension is obvious. Revenue is still contracting — down 22% year-over-year — and management guides Q3 to $44-48M, essentially flat. The retail lift is a six-to-twelve-month planogram game, and the market is pricing continued decline rather than inflection: price-to-revenue sits at just 0.2x. The bull case rests on whether the nutrition-led, multichannel model can convert the 2027 planogram resets into genuine growth. The GLP-1 tailwind gives this small-cap turnaround a rare, differentiated catalyst — and a reason to watch the next two quarters closely.